Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086222 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of NVX-CoV2705
A Phase 4 study, sponsored by Novavax.
- Active
- Registry status
- Phase 4
- Development phase
- 6,500
- Enrollment target
NCT07086222 is a Phase 4 study that is active but no longer recruiting, run by Novavax. The registered enrollment target is 6,500 participants.
The verdict
NCT07086222, a Phase 4 study, is active but no longer recruiting, sponsored by Novavax.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 6,500 participants
- Enrollment target
Study Summary
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NVX-CoV2705
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,500 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2026-11-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086222
The ClinicalTrials.gov registry entry for NCT07086222 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 6,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07086222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07086222 about?
NCT07086222 is a clinical study titled "Efficacy and Safety of NVX-CoV2705". This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
What is the current status of trial NCT07086222?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 6,500 participants. The study started on 2025-11-20. Estimated completion is 2026-11-18.
What interventions are being tested in trial NCT07086222?
The interventions under investigation include: Placebo (BIOLOGICAL), NVX-CoV2705 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07086222?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.